22 November 2021
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
Director's Dealing
Alliance Pharma plc (AIM: APH), the international healthcare group, announces that it has today received notice that Peter Butterfield, Chief Executive Officer of Alliance, exercised options over 500,000 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") under the Company's Share Option Plans at an exercise price of 47.5 pence per share (granted in 2016). These were net settled by the Company of which 230,583 shares were not issued as a result of the net settlement.
As such, following this exercise, 269,417 Ordinary Shares were sold at a price of 102.5p pence per share, in part to satisfy costs and tax liabilities. In accordance with the Group's share retention policy, following this transaction, Mr Butterfield has a beneficial interest in 442,104 Ordinary Shares and 1,750,000 vested but unexercised share options. Mr Butterfield continues to maintain his 200% of salary holding requirement.
The notification below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a) |
Name |
Peter Butterfield |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Chief Executive Officer |
|
|
b) |
Initial notification /Amendment |
Initial Notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
ALLIANCE PHARMA PLC |
|
|
b) |
Legal Entity Identifier |
213800RYIWZA4Q5WPZ13 |
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary shares of 1 pence each
GB0031030819 |
|
|
b) |
Nature of the transaction |
a) Exercise of options b) Sale of Ordinary Shares |
|
|
c) |
Currency |
GBP |
|
|
d) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
a) 47.5 pence b) 102.5 pence
|
a) 500,000 b) 269,417 |
||
|
|
|
||
|
e) |
Aggregated information - Aggregated volume - Price - Aggregated total |
a) 500,000 options over Ordinary Shares, at an exercise price of 47.5 pence per Share.
b) 269,417 Ordinary Shares, sold at an average price of 102.5 pence per Ordinary Share, totalling £276,152
|
|
|
f) |
Date of the transaction(s) |
19 November 2021 |
|
|
g) |
Place of the transaction |
London Stock Exchange, AIM |
|
For further information:
|
Alliance Pharma plc |
+ 44 (0)1249 466966 |
|
Peter Butterfield, Chief Executive Officer |
|
|
Andrew Franklin, Chief Financial Officer |
|
|
www.alliancepharma.co.uk |
|
|
Buchanan |
+ 44 (0)20 7466 5000 |
|
Mark Court / Sophie Wills / Hannah Ratcliff |
|
|
|
|
|
Numis Securities Limited |
+ 44 (0)20 7260 1000 |
|
Nominated Adviser: Freddie Barnfield / Duncan Monteith |
|
|
Corporate Broking: James Black |
|
|
Investec Bank plc |
+ 44 (0) 20 7597 5970 |
|
Corporate Finance: Daniel Adams |
|
|
Corporate Broking: Patrick Robb |
|
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.
We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.
Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.
For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
